November, 2022 Crucial LLS Support Drives Approval of New Precision Medicine for Rare Group of Blood Diseases
November, 2022 Over 50% of Patients With R/R Acute Leukemias Respond to SNDX-5613 in AUGMENT-101
November, 2022 First Patient Dosed With Menin Inhibitor BMF-219 in COVALENT-101 Trial in CLL
https://www.onclive.com/view/first-patient-First Patient Dosed With Menin Inhibitor BMF-219 in COVALENT-101 Trial in CLLdosed-with-menin-inhibitor-bmf-219-in-covalent-101-trial-in-cll
November 8, 2022 Oral Azacitidine Confers Survival Benefits in Patients With Acute Myeloid Leukemia
November, 2022 Study Identifies Novel Therapeutic Target for Acute Myeloid Leukemia
November, 2022 The mycotoxin viriditoxin induces leukemia- and lymphoma-specific apoptosis by targeting mitochondrial metabolism
November, 2022 Iomab-B With Subsequent Bone Marrow Transplant Meets dCR End Point in Relapsed/Refractory AML
November, 2022 Gilead and Kite Oncology Demonstrate Transformative Impact of Cell Therapy and Promise of Blood Cancer Portfolio at ASH 2022
November, 2022 Germline ATM Variants Impact Development of CLL
October, 2022 FDA Grants Priority Review to Quizartinib for Newly Diagnosed FLT3-ITD–Positive AML
October, 2022 FDA Grants Fast Track Designation to MT-101 for CD5+ Relapsed/Refractory PTCL
October, 2022 Lisaftoclax in Combination with Alrizomadlin Overcomes Venetoclax Resistance in Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia: Preclinical Studies
October, 2022 Recent Updates in Diagnosing and Treating Acute Lymphoblastic Leukemia
October, 2022 FDA Broadens Treatment Options for Relapsed/Refractory Multiple Myeloma
October, 2022 Zanubrutinib Shows Superior Progression-Free Survival vs Ibrutinib in Chronic Lymphocytic Leukemia
Leukemia is cancer of the body’s blood-forming tissues, including the bone marrow and lymphatic system. Leukemia begins in a cell in the bone marrow, the spongy center inside of the bones where cells develop from stem cells into red cells, white cells or platelets. In leukemias, the cell mutates and becomes a type of leukemia cell classified by type of cell and by pattern of growth.
Lymphoid cells and Myeloid cells: the marrow forms myeloid cells which normally go on to form red cells. Myeloid leukemia can begin in these cells. The marrow also forms lymphocytes, the infection-fighting cells of the immune system. Lymphocytic leukemia can arise in these cells.
Acute and Chronic Leukemias: leukemias are also classified by how quickly they progress, in acute leukemia, immature white blood cells multiply rapidly in the bone marrow and are called blasts. Instead of functioning properly as the body’s infection fighters, these abnormal cells fill the blood, leaving little space for healthy cells. Acute leukemias progress rapidly without treatment. In chronic leukemia, the cancer develops more slowly, and is often diagnosed due to enlargement of the spleen.
The four main types of leukemias include:
Acute myeloid leukemia and acute lymphocytic leukemia-in these diseases, the acute leukemia cell multiplies to form a trillion more leukemia cells. Unlike healthy cells, these cells are called ‘nonfunctional’ because they do not function as normal and crowd out the normal cells in the marrow. With the resulting decrease in healthy red cell production, patients often experience anemia and increased bleeding and infection risks.
Chronic myeloid leukemia-the cell that begins this disease makes mature blood cells that function similar to normal cells. The number of red blood cells produced is usually less than normal, while the white blood cell count increases, which can result in severe anemia.
Chronic lymphocytic leukemia-the cell that begins this disease makes too many non- functioning lymphocytes. These cells interfere with the normal lymphocytes, causing a decrease in healthy red and white cell counts, and a weakened immune system. CLL is characterized by slow disease progression, often not requiring treatment for long periods of time.
The progress that has been made in treating leukemia gives patients and caregivers more hope than ever before. Treatments may include targeted drug therapy, chemotherapy, monoclonal antibody therapy, stem cell transplantation, and radiation therapy.
Acute Leukemia: treatments for patients with acute leukemias may include chemotherapy, targeted drug therapy and stem cell transplants. Treatment for both acute lymphoblastic leukemia (ACL), and acute myeloid leukemia (AML) usually need to start treatment soon after diagnosis. Treatment usually commences with a chemotherapy regime called induction therapy. Induction therapy kills leukemia in the blood and bone marrow to induce remission. If the specific genetic mutation called the Philadelphia chromosome is present, a tyrosine kinase inhibitor may be added to the treatment protocol. Induction therapy is often followed by consolidation therapy and may include stem cell transplantation. Follow up maintenance therapy may include lower doses of chemotherapy for up to three years.
Chronic myeloid leukemia (CML): treatment usually starts soon after diagnosis and is based on the genetics of the abnormal myeloid cells. Induction therapy kills leukemia in the blood and bone marrow to induce remission by chemotherapy treatment and may also include the approved targeted drugs for CML, Gleevec, Sprycel, or Tasigna. Post-remission therapy kills residual cancer cells and may include a stem cell transplant. Chemotherapy may be given in lower doses and frequency.
Chronic lymphocytic leukemia (CLL): Some CLL patients require only “watch and wait” observation after diagnosis. Patients who do need treatment may receive chemotherapy, targeted drug therapy/immunology therapy or combination therapy. Radiation therapy may be used to treat lymph node involvement.
Clinical Trials for Leukemia at MHOA
Leukemia & Lymphoma Society Clinical Trials
Leukemia Trials/ National Cancer Institute
American Cancer Society
CenterWatch Trials: Acute Myelogenous Leukemia
CenterWatch: Leukemia Trials
Cancer Care Educational Resource for Leukemia
Leukemia & Lymphoma Society Resource Center
Leukemia Research Foundation
American Cancer Society Resources for Acute Lymphocytic Leukemia
National Cancer Institute
ACOR.org Association of Cancer Online Resources
Oncolink: Cancer resources for patients and healthcare professionals
CRISPR-Based System Identifies Important New Drug Targets in a Deadly Leukemia-Cold Spring Harbor Laboratory March 8, 2018 https://medicalxpress.com/news/2018-03-crispr-based-important-drug-deadly-leukemia.html
New Therapies for Acute Leukemia
New Drug target for leukemia identified
Medical News Today
July 31, 2014
European Commission Approves Roche Leukemia Treatment
The Wall Street Journal
July 29, 2014
FDA expands approved use of Imbruvica for chronic lymphocytic leukemia
FDA News Release
July 28, 2014
FDA approves idelalisib for three leukemia and lymphoma indications
The Oncology Report
July 23, 2014
Novartis Wins ‘Breakthrough’ Status for New Leukemia treatment
The Wall Street Journal
July 7, 2014
Now Enrolling Patients for AML and CLL Clinical Trials at Manhattan Hematology Oncology Associates.Read More
Leukemia & Lymphoma Society Support groups
Acute Myelogenous Leukemia AML Support Group
Acute Lymphocytic Leukemia ALL Support Group
MD Junction Acute Myelogenous Leukemia Support Group
ACOR Association of Cancer Online Resources
Caring4Cancer Support Groups
The National CML Society
Inspire Support Groups
Imerman Angels (to connect directly with another survivor or caregiver through an organization that creates personal, one-on-one connections among patients, survivors, and caregivers)
Fighting Chance- free counseling service for cancer patients and caregivers